Posted by Michael Wonder on 24 Oct 2021
Small Pharma granted fast track designation from UK regulator for DMT assisted therapy for major depressive disorder
21 October 2021 - Small Pharma is pleased to announce that following discussions with the U.K. MHRA, Small Pharma has been granted an Innovation Passport Designation for SPL026, the lead product candidate from its pipeline of N,N-dimethyltryptamine (“DMT”) assisted therapies for the treatment of major depressive disorder.
DMT is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals.
